Ignite Creation Date:
2024-05-06 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 12:45 PM
Study NCT ID:
NCT03525795
Status:
COMPLETED
Last Update Posted:
2022-05-18
First Post:
2018-04-23
Brief Title:
ORIOn-E A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
Sponsor:
Constellation Pharmaceuticals
Organization:
Constellation Pharmaceuticals
Study Overview
Official Title:
A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 12 multi-center open-label study of CPI-1205 ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors This study is designed to determine the maximum tolerated dose MTD and recommended phase 2 dose RP2D of CPI-1205 ipilimumab in patients with advanced solid tumors Patients in Phase 2 will be treated at the RP2D of CPI-1205 ipilimumab
This study was stopped prior to proceeding to Phase 2 no patients were enrolled in Phase 2
This study was stopped prior to proceeding to Phase 2 no patients were enrolled in Phase 2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None